Aeglea BioTherapeutics, Inc. (AGLE)
(Delayed Data from NSDQ)
$6.96 USD
+0.24 (3.57%)
Updated May 3, 2019 04:00 PM ET
After-Market: $6.94 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.96 USD
+0.24 (3.57%)
Updated May 3, 2019 04:00 PM ET
After-Market: $6.94 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Take the Zacks Approach to Beat the Market: Shopify, Oracle, Uber in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Aeglea (AGLE) Soars 329% on Acquiring Spyre Therapeutics
by Zacks Equity Research
Aeglea's (AGLE) shares surge as it acquires Spyre Therapeutics, a private company that focuses on developing antibody therapeutics for inflammatory bowel disease.
Aeglea Biotherapeutics (AGLE) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aeglea (AGLE) delivered earnings and revenue surprises of -5.26% and 16.47%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
CytomX Therapeutics (CTMX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 68.75% and 5.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Aeglea (AGLE) Plunges 26% After Rare Disorder Drug Study Fails
by Zacks Equity Research
Aeglea BioTherapeutics (AGLE) announces failure to meet goals in the phase I/II study of pegtarviliase for the treatment of Classical Homocystinuria. The stock is down 26% following the news.
Aeglea Biotherapeutics (AGLE) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Aeglea (AGLE) delivered earnings and revenue surprises of 10% and 1.18%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
G1 Therapeutics (GTHX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 14.12% and 6.64%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Kymera (KYMR) Up on Positive Data From Phase I Study on KT-474
by Zacks Equity Research
Kymera (KYMR) posts positive data from a phase I study on KT-474 for treating patients with hidradenitis suppurativa and atopic dermatitis. Sanofi to advance KT-474 in phase II study.
Sanofi's (SNY) Dupixent Gets Europe Nod for Prurigo Nodularis
by Zacks Equity Research
The EC approves Sanofi (SNY) and its partner Regeneron's Dupixent for the treatment of adult patients with prurigo nodularis.
Aeglea (AGLE) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Aeglea (AGLE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Valneva (VALN) Up on Antibody Persistence Data on Chikungunya Jab
by Zacks Equity Research
Valneva (VALN) posts encouraging 12-month antibody persistence data for its single-shot chikungunya vaccine candidate, VLA1553. Shares rise.
BEAM Up as FDA Lifts Clinical Hold on the IND for BEAM-201
by Zacks Equity Research
The FDA lifts the clinical hold on BEAM's investigational new drug application for BEAM-201 to treat relapsed/refractory T-cell acute lymphoblastic leukemia/T-cell lymphoblastic lymphoma. Stock up.
Novartis' (NVS) Pluvicto Meets Goal in 2nd Prostate Cancer Study
by Zacks Equity Research
Novartis' (NVS) phase III PSMAfore study evaluating Pluvicto for treating patients with PSMA-positive metastatic castration-resistant prostate cancer meets primary endpoint.
BioNTech (BNTX) Inks Research Deal With Ryvu Therapeutics
by Zacks Equity Research
BioNTech (BNTX) signs a research collaboration agreement with Ryvu Therapeutics to develop small molecule programs targeting immune modulation in cancer and other diseases. Stock up.
Seagen (SGEN) Adcetris Label Expansion OK'd, New CEO Named
by Zacks Equity Research
The FDA approves Seagen's (SGEN) Adcetris for a new indication, treating pediatric patients with previously untreated high-risk Hodgkin lymphoma. The company also appoints a new CEO.
Aeglea Biotherapeutics (AGLE) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Aeglea (AGLE) delivered earnings and revenue surprises of 20.83% and 72.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Seres Therapeutics (MCRB) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -8.89% and 71.97%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Gilead (GILD) Inks Deal for Gene Platform in Blood Cancers
by Zacks Equity Research
Gilead (GILD) signs a license agreement with Refuge Biotechnologies to use the latter's gene expression platform to develop treatments for blood cancers.
AbbVie (ABBV) to Boost Immunology Pipeline With New Acquisition
by Zacks Equity Research
AbbVie (ABBV) acquires UK-based DJS Antibodies Ltd to enhance its antibody research activities and strengthen the immunology portfolio.
Immunovant (IMVT) Set to Develop Lead Candidate Batoclimab
by Zacks Equity Research
Immunovant (IMVT) expects its lead pipeline candidate, batoclimab, being developed for treating several types of autoimmune diseases, to capture good market share, owing to its differentiated profile.
NeuBase (NBSE) Up on Restructuring Plan, Set to Lower Workforce
by Zacks Equity Research
NeuBase (NBSE) intends to reduce its existing workforce by nearly 60%. The company plans to maximize shareholder value and focus on the advancement of its platform in gene editing. Stock up.
Aeglea (AGLE) Down on Corporate Restructuring, CEO Steps Down
by Zacks Equity Research
Aeglea (AGLE) announces a corporate restructuring plan to prioritize the development of AGLE-177 for patients living with homocystinuria. The company's current CEO resigns. Stock down.
Aeglea BioTherapeutics (AGLE) Seeks EU Nod for ARG1-D Treatment
by Zacks Equity Research
Aeglea BioTherapeutics (AGLE) seeks a nod for its lead candidate, pegzilarginase, for treating ARG1-D in the European Union. Stock surges post announcement.
Aeglea Biotherapeutics (AGLE) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Aeglea (AGLE) delivered earnings and revenue surprises of -3.85% and 55.99%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Acadia (ACAD) Down More Than 30% in Past 3 Months: Here's Why
by Zacks Equity Research
The recent setback faced by Acadia's (ACAD) resubmitted sNDA for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with ADP has hurt the stock.